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ABSTRACT 
Objective: This study aimed to develop a novel topical ocular system of natamycin (NAT) by formulating and evaluating of NAT-solid lipid 
nanoparticle (SLN) loaded on mucoadhesive gels to improve its therapeutic activity and reduce the frequency of dosage to assist patient compliance.  
Methods: SLNs were prepared using lipids and Tween 80 or Pluronic F127 as stabilizers via modified high shear homogenization and ultrasound 
techniques. The prepared SLNs were characterized for particle size (PS), zeta potential (ZP), polydispersity index (PI), and entrapment efficiency 
percentage (EE %). The morphological examination for chosen SLNs was done using a transmission electron microscope (TEM). Carbapol 940 and 
Hydroxypropyl methylcellulose (HPMC) was incorporated with selected NAT-SLNs to form mucoadhesive gels. The prepared NAT-SLN gels were 
evaluated for drug content, mucoadhesion force, release study, and in vitro microbiological activity. In vivo study for the chosen formulae was done 
to evaluate its efficacy against keratitis in rabbits.  
Results: NAT-SLNs exhibited high EE % up to 99.167% and PS ranging from 128.35 to 1719.5 nm, with negatively charged ZP that confirmed the 
stability of SLNs. The NAT-SLN gels provided the high mucoadhesive force with a controlled release manner compared with the marketed-product 
MP. The in vivo experimental studies and histopathological examination showed the superiority of G2 (NAT-SLN (5% Pluronic F127 and 1:1 mixed 
lipid) 4% HPMC) over MP against Candida keratitis. 
Conclusion: According to the obtained results, G2 provided an effective pharmaceutical system against fungal keratitis in a controlled release 
manner compared with MP for reducing dosage frequency.  
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INTRODUCTION 
Fungal keratitis is the most common cause of corneal blindness. The 
incidence of such type was notified to be between 17% and 36% [1]. 
Three different classes of antifungal agents; echinocandins, azoles, and 
polyenes (natamycin, amphotericin B, and nystatin) were used for the 
treatment of fungal keratitis [2-4]. Natamycin (NAT) is the first 
antifungal agent for topical ophthalmic administration, approved by 
the Food and Drug Administration of the United States [5]. It is 
commercially available as NATACYN 5% ophthalmic suspension eye 
drop; Alcon. It was rated to be a broad-spectrum antifungal agent 
against filamentous mycotic keratitis (MK) by binding to ergosterol in 
the fungal cell membrane. NAT provides higher penetration ability 
across the intact cornea upon topical application comparable to the 
other antifungal agents [6]. The sitting therapy with NAT reported 
unsatisfactory performance because of the long duration of treatment, 
high dosing frequency, and short residence time at the ocular mucosa 
[7]. This prolonged and high-frequency dosing is difficult to attain, 
causing suboptimal concentration at the infected corneal site and 
increased resistance to MK [7, 8]. Novel carrier systems, such as solid 
lipid nanoparticle (SLN), would provide great potential for improving 
ocular drug bioavailability. SLNs are sub-micron colloidal carriers that 
are consisted of physiological lipids, suspended in an aqueous 
surfactant solution. SLNs have several advantages over the traditional 
forms; they can encapsulate the drug to work as a drug reservoir 
leading to control and target release of the drug. They are non-
immunogenic biocompatible and biodegradable carriers [9, 10]. SLNs 
provide a new tool for formulating systems to enhance the corneal 
permeability and absorption of the loaded drug because of their 
lipophilic characteristics and nanosize [11]. Recently, Singh et al. [12] 
developed SLN for ocular delivery of isoniazid that showed significant 
in vitro and in vivo uptake of fluorescein-labeled SLN, and corneal 
permeability enhancement. The SLN dispersions were still in non-
adhesive liquid form that could be easily cleared from the eye because 
of high tear fluid turnover and dynamics. A significant number of 
studies on rabbits demonstrated that higher bioavailability and 
sustained activity of the drugs obtained with semisolid preparations 
containing mucoadhesive polymers such as Carbapol, cellulose 
derivatives, and polyvinyl alcohol [13, 14]. According to many studies, 
hydrogels formed from water-soluble polymers were suggested as 
vehicles for the prepared SLN for a good viscosity and satisfactory bio-
adhesion to provide intimate contact of SLNs with the absorbing 
surface and increase the residence time of the drug at the cornea 
without irritating actions [15]. In the present study, ocular NAT-SLN 
loaded mucoadhesive gels were formulated and evaluated to provide a 
non-invasive mucoadhesive ocular system in an effective and 
controlled release manner to enhance precorneal residence time, 
reduce dosing frequency and improve patient compliance. 
MATERIALS AND METHODS 
Materials 
Natamycin was purchased from Sigma Chemical Co. St. Louis, MO, 
USA. NATACYN® Ophthalmic Suspension, Alcon Laboratories, INC. 
(USA). Stearic acid was kindly gifted from Global Napi 
Pharmaceuticals Company, Egypt. Tween 80 was purchased from 
EL-Nasr Pharmaceutical Chemicals Company, Abu Zaabal, Cairo, 
Egypt. Compritol ATO 888 was kindly gifted from Gattefosse 
Company, France. Methanol, sodium chloride, sodium bicarbonate, 
dimethyl sulfoxide, and calcium chloride.2H2O were purchased from 
EL-Nasr pharmaceutical Chemicals Company, Abu Zaabal, Cairo, 
Egypt. Triethanolamine (E. Merk, Germany). Carbopol 940 (B. F., 
Goodrich Chemical Company, Ohio, USA). Hydroxypropyl 
methylcellulose (HPMC) was purchased from Tama, Tokyo, Japan. 
Methods 
Formulation of natamycin-solid lipid nanoparticles (NAT-SLNs) 
NAT-SLNs were prepared by modified high shear homogenization 
and ultrasound technique using Compritol ATO 888 and Stearic acid 
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as lipids and Tween 80 or Pluronic F127 as a surfactant. The lipid–
drug mixture was heated and maintained at 80 °C that transcended 
the lipid melting temperature. An aqueous phase was prepared by 
dissolving the weighed surfactant in distilled water then heated to 
the same temperature of the lipid phase. This hot aqueous phase 
was added to the lipid phase and homogenized by using a 
homogenizer (Heidolph, Germany) at 21,000rpm for 10 min. Hot 
coarse oil in water emulsion was obtained and ultrasonicated using 
a probe sonicator (ultrasonic processor, GE130, probe CV18, USA) 
for 10 min to form hot SLN. The hot SLNs were finally cooled at 
room temperature [16]. Table 1 shows the composition of twelve 
prepared SLNs using different types of lipids and surfactants. 
  
Table 1: Composition of prepared natamycin solid lipid nanoparticles (NAT-SLNs) 
Formula Drug (mg) Surfactant (gm %) Lipids (gm %) 
Tween 80  Pluronic F127  Compritol ATO888  Stearic acid  
F1 15 4 - 5 - 
F2 15 - 4 5 - 
F3 15 5 - 5 - 
F4 15 - 5 5 - 
F5 15 4 - - 5 
F6 15 - 4 - 5 
F7 15 5 - - 5 
F8 15 - 5 - 5 
F9 15 4 - 2.5 2.5 
F10 15 - 4 2.5 2.5 
F11 15 5 - 2.5 2.5 
F12 15 - 5 2.5 2.5 
 
Pharmaceutical evaluation of NAT-SLNs 
Particle size (PS), zeta potential (ZP) and polydispersity index 
(PI) determination 
The mean vesicle diameter and PI of NAT-SLNs were estimated by 
the Dynamic Light Scattering (DLS) technology with a Zetasizer 
Nano ZS (Software Ver 6,20. Malvern instruments; Worcestershire, 
UK). The measurements were performed after dilution of each SLN 
by 100 fold of deionized water to achieve a suitable scattering 
intensity at 90 ° for the incident beam. The Laser Doppler 
Anemometer, coupled with the same equipment, was used for 
estimation of the ZP (ζ) values of the prepared systems. This 
technique analyzed the electrophoretic mobility of vesicles under an 
electric field, after convenient dilution with a large amount of 
bidistilled water [17]. The three successive measurements of 
independent samples were performed for this test. 
Determination of NAT entrapment efficiency percentages (EE %)  
The entrapment efficiency percentages (EE %) of NAT in different 
SLNs were determined by the dialysis method. In this method, a 
dialysis bag holding 1 ml of SLN was obscured in 30 ml of 1% tween 
aqueous solution (dialysis medium) and stirred with a paddle at 
37±0.5 C. Dialysis was proceeded for 1 hr. Then, aliquots of the 
dialysis medium were withdrawn from the dissolution cup and 
filtered through a 0.45 µm filter membrane. The drug-free 
percentages were determined spectrophotometrically at specific 
λmax (316.7 nm) using UV spectroscopy (Shimadzu-1650 PC double 







Dt: the total amount of NAT in the SLN  
Dd: the amount of NAT that diffused into the receiver medium  
The results were shown as an average of three independent 
experiments for each formula.  
Morphological examination via transmission electron 
microscopy (TEM)  
The morphology of NAT-SLN was examined using a transmission 
electron microscope (TEM) (Jeol JEM 1230, Tokyo, Japan) at 70 kV 
after 50 fold dilution of SLN with distilled water. In this technique, 
one drop of each diluted SLN was placed on the surface of a 300 
mesh carbon-coated copper grid and left to settle for 3-5 min. The 
excess fluid was isolated with a filter paper and allowed to dry at 
room temperature for 10 min before examination under a 
transmission electron microscope at 70kV [17, 19]. 
Formulation of NAT-SLN loaded gels 
23factorial design was used to optimize the formulation of NAT-SLN 
loaded gels. This study design involved three types of factors, 
namely: two selected SLN dispersions (F5, F12), two types of 
polymers (Hydroxypropyl methylcellulose HPMC, Carbapol 940), 
and each polymer at two levels (Carbapol 940 “1-2%” and HPMC “2-
4%”). All compositions of eight prepared NAT-SLN loaded gels were 
collected in table 2. The selected SLNs were incorporated in 
different gel forms using two different polymers; HPMC and 
Carbapol 940. The weighed amount of HPMC or Carbapol 940 was 
sprinkled while stirring to 1/3 of the required amount of distilled 
water at 80 °C to form gels. The net volume was adjusted to 100 ml 
by distilled water containing NAT-SLN. In the case of Carbapol gel, 1 
ml triethanolamine was added to form the base. The gels were left 
overnight in the refrigerator [20]. 
 
Table 2: The composition of NAT-SLN in ocular gels 
Carbopol 940 (%W/W) HPMC (%W/W) SLN dispersions Formula 
- 2 F12 G1 
- 4 F12 G2 
1 - F12 G3 
2 - F12 G4 
- 2 F5 G5 
- 4 F5 G6 
1 - F5 G7 
2 - F5 G8 
Abbreviations: SLN, solid lipid nanoparticle; HPMC, Hydroxypropyl methylcellulose 
Characterization of the formed NAT-SLN loaded gels
Visual inspection 
The freshly prepared gels were visually inspect
background. The appearance and other physical 
(precipitation, color, and homogeneity) were evaluated
Determination of drug content 
In an incubator shaker (JEIO Tech SI-300 Lab Companion, 
Koea), 1g of each ocular gel was shaken with 100 ml
for 1h to ensure complete dissolution. Samples were 
and filtrated. NAT was assayed spectrophotometrically at λ
using UV spectroscopy (Shimadzu-1650 PC double beam, Japan). The 
percentage of NAT was calculated as the mean of three recordings
[20]. 
Determination of mucoadhesion force for gel formulae
The experimental technique used for the estimation 
bioadhesive force was obtained from an already
[21]. The apparatus (locally made) was designed for measuring the 
minimum weight required to detach two membranes from each 
other with gel form spread in-between them. 
setup is presented in fig. 1. The minimal weight of water 
detach the sample from the small intestine of the rabbit
the mucoadhesive force. The mucoadhesive force
stress (dyne/cm2)) was calculated using the following equatio
Detachment stress (dyne/cm2) =
Where:  
m: the weight of water 
g: acceleration due to gravity is taken as 981 cm/
A: area of rabbit’s small intestine (area of contact)
 
Fig. 1: Mucoadhesive-force-measuring devic
inverted beaker, (F) hot plate, (G) dropping
  
In vivo antifungal evaluation study 
This study was approved by the institutional animal ethics 
committee, Cairo University, Egypt (PI 1866)
conducted on twelve rabbits weighing 1.5-2.5 kg with a 
eating only green food. In the operating room, all rabbits were 
sedated using an intramuscular injection of 1 ml (50 mg
ketamine (Ketalar VR). Benoxinate eye drops 
conjunctival sac of all rabbits’ eyes for topical anesthesia
all rabbits were marked, followed by the scrapping of corneal 
epithelium. Candida was injected using needle 27gauge
Candida Albicans with a concentration of 5 × 105 cells
posterior corneal stroma [24]. The whole procedure was done under 
complete aseptic conditions, with the aid of a binocular micros
and washing the eyes with chloramphenicol eye drops. 
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This experiment was formed for 
manner. 
Study of NAT release profile from SLN loaded gel
This study was performed using a modified USP dissolution 
apparatus II (Dr. Schleuniger Pharmaton, type Diss 6000, 
Switzerland). A 10 ml capacity syringe was designe
by smoothly removing the whole diameter near the nozzle [22]. The 
bottom of the syringe was then tightly covered with a piece of cloth 
supported by a wire mesh. The weighed one gram of each gel 
formulae was placed into the syringe from t
the pump then attached to the rotating paddle. The syringe tube was 
immersed in the vessel containing 100 ml artificial tear fluid buffer 
pH=7.4 at 37 °C±0.5 with a paddle speed of 50 rpm. A sample of 2 ml 
was taken at a determined ti
replaced with a fresh release medium. The released drug amount in 
the withdrawn samples was detected spectrophotometrically versus 
marketed product MP (NATACYN ophthalmic suspension) at λ
(316.7 nm). The results were re
(n=3) for each formula. 
Antifungal activity study 
In vitro antifungal study (cup method)
The in vitro antifungal activities of gel formulae and MP were 
examined using the agar cup diffusion method against 
Albicans strain (supplied from the department of microbiology, 
Faculty of Veterinary, Cairo University). Sabouraud dextrose agar in 
cups of 10 mm diameter was prepared under aseptic condition then 
inoculated with tested fungal suspension strain by spreading on the 
agar surface. The cups were filled with 100 mg of each gel formula of 
the antifungal drug and MP as standard by a sterile syringe. The 
formed inhibition zones for gel forms and MP were measured in 
triplicate measurements [23]. 
e: (A) modified balance, (B) section of rabbit small intestine
 bottle, (H) infusion apparatus, (I) Beaker, (J) thin steel wire
. This study was 
healthy eye, 
/ml) 
were applied to the 
. Corneas of 




the flourishing of the organism
investigation for infection signs
The treatment was initiated, where
groups and given codes (A, B). The
in each group received a different antifungal 
rapid release formula MP (NATACYN® (5% ophthalmic suspension)
was placed as one drop in the conjunctival sac at 
intervals (usual dose regimen)
formula (G2) was applied 300 mg three
cases, the left eyes were kept untreated
equal volume of saline solution.
set daily for 2w. Treatment and comments w
ophthalmologist, who did not know the 
formulae MP and G2 and were
m, Vol 12, Issue 5, 2020, 173-180 
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each prepared gel in a triplicate 
 
d to act as a tube 
he top after removing 
me interval over 6h and instantly 
max 




, (C) 100g weight, (D) gel film, (E) 
, (K) balance bar 
 would be confirmed by corneal 
.  
 all rabbits were divided into two 
 right infected eyes of all rabbits 
formula. Group A: the 
 
one or two-hour 
. Group B: the sustained release 
 times daily (every 8h). In all 
 as control and received an 
 The therapy of these formulae was 
ere done by an 
difference between the two 
 blinded in order not to be biased. 
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Photos were taken along the whole procedure for documentation, 
from the start of infection to the last day of treatment. 
Histopathological evaluation of corneal specimens 
Two weeks later, rabbits were slaughtered and the corneas were 
dissected at the limbus and sent to the department of pathology, 
Kasr Al-Aini Hospital, Cairo University, under complete aseptic 
conditions in 10% formaldehyde solution for histopathological 
evaluation. Specimens of the cornea were taken and instantly fixed 
in 10% neutral buffered formalin. After suitable fixation, the 
specimens were dehydrated in alcohol, cleared in xylol, and 
obscured in paraffin. Paraffin sections of 5µ thickness were cutted 
and stained with hematoxylin and eosin (H and E). The H and E 
stained slides were examined under a light microscope for 
inflammation reaction and the presence or absence of fungal spores.  
RESULTS AND DISCUSSION 
Formulation of NAT-SLN  
Modified high shear homogenization and ultrasound technique is an 
ideal method used for NAT-SLNs preparation. This method is water-
based technology that forms safe, organic solvent-free nanoparticles 
for ocular delivery. Also, it is reproducible, easy to apply, and gave 
satisfying results that indicated the success of this method for 
preparation [16]. 
Pharmaceutical evaluation of NAT-SLN 
Particle size (PS), zeta potential (ZP) and polydispersity index 
(PI) measurements  
The mean PS, ZP, and PI values of the developed SLNs are shown in 
table 3. The mean PS of SLNs was in the range of (1719.5 nm (F3) to 
128.35 nm (F5)). Interestingly, Compritol ATO 888 was found to 
increase the PS when compared with Stearic acid or mixed lipids. 
This could be attributed to that Compritol ATO 888 possesses a 
higher melting point (69-74 °C) in comparison with stearic acid (55 
°C). It was stated that the PS of SLNs was increased with higher 
melting lipids. Similarly, Zhuang CY et al. [25] found that compritol 
ATO 888 with a higher melting point formed larger SLNs. Besides, 
lipids having shorter hydrocarbon chain length as stearic acid (C18) 
provided SLNs with smaller PS in comparison to those produced by 
lipids of longer chains as Compritol ATO 888 (C22). On the other 
hand, the present results showed that Pluronic F127 increased PS 
when compared with Tween 80. PI values of the prepared SLNs 
were found below 1 that indicated the uniformity of fine vesicle size 
distributions [26]. ZP values of all prepared SLNs were negatively 
charged. This negative charge was probably raised due to the 
slightly ionized fatty acids from the glycerides used (Compritol ATO 
888 and Stearic acid). The results showed that the highest ZP value-
23.8 mV was obtained in case of F1, prepared using 4% tween 80 
and 5% Compritol ATO 888 and the lowest ZP value-15.4 mV was 
obtained in case of F9, prepared using 4% Tween 80 and 1:.1 
Compritol ATO 888 and Stearic acid. The steric stabilizers (Tween 
80 and Pluronic F127) preferred for the formation of stable 
nanoparticle dispersion. Due to the presence of such stabilizer, all 
prepared SLNs had negative ZP values above |8-9| mV, which was an 
indication for the SLNs stability [17, 27, 28]. 
Entrapment efficiency percentage (EE %) determination 
The entrapment efficiency percentage (EE %) of NAT in the different 
formed SLNs is shown in table 3. From the showed results, SLNs 
containing Compritol ATO 888 had higher EE than Stearic acid and 
mixed lipids’ SLNs. Since Compritol ATO 888 is a mixture of mono-, 
di-and triglycerides and also having fatty acids of different chain 
lengths, these formless perfect crystals with many defects formed 
space to accommodate the drug [29]. Besides, the EE of the prepared 
SLNs was increased by increasing the lipophilicity of the used lipid. 
Applying the fact that an increasing in alkyl chain length increases 
the lipophilicity of the molecules [30], Compritol ATO 888 (C22) is 
more lipophilic than Stearic acid (C18). Therefore, Compritol ATO 
888 had higher accommodation of lipophilic drugs such as NAT in 
comparison with Stearic acid. This comes in agreement with 
Ruktanonchai et al. [31], who found that lipids of higher lipophilicity 
entrapped drugs more efficiently. Also, it was reported that particles 
of larger size possessed higher EE. Therefore, the higher EE of 
Compritol ATO 888 SLNs participated in their larger particle size 
when compared to stearic acid SLNs and mixed lipids. It was 
observed that Pluronic F127 increased the entrapment efficiency 
compared to Tween 80. This can be explained by higher HLB 22 and 
the long hydrophobic polypropylene oxide segment leading to the 
formation of stable micelles with more drug retention capacity than 
Tween 80 [32]. Moreover, this could commonly be explained by an 
important factor, which is gel to liquid phase transition temperature 
(T °C) of the surfactant, which is directly proportional to the surfactant 
alkyl hydrocarbon chain length. Surfactants of lower (T °C) like Tween 
80 (HLB=15) containing shorter chains, consequently having lower EE. 
This result also coincided with Guinedi et al. [33], who proved that the 
EE was not controlled by the surfactant´s HLB only but also by the 
chemical structure of the surfactant related to the length of the alkyl 
chain. Surfactants of longer saturated alkyl chains exhibited higher EE. 
The PS of SLNs was increased proportionally with increasing of the 
surfactant HLB values because of the decreasing surface free energy. 
The decreasing of surface free energy caused increasing of surfactant 
hydrophobicity that consequently increased drug entrapment. 
Therefore, SLNs containing Tween80 had lower EE than SLNs 
containing Pluronic F127. 
 
Table 3: The PS, ZP, PI and EE % values of NAT-SLN formulae 
Formula PS (nm) ZP (mV) PI EE (%) 
F1 361.4±0.9 -23.8±2.8 0.6155±0.03 99.167±0.5 
F2 484.6±1.2 -19.65±1.50 0.821±0.02 99.231±0.09 
F3 1719.5±0.78 -17.35±3 1±0.03 98.1±0.57 
F4 550.85±2.3 -18.3±0.9 0.343±0.06 98.89±1 
F5 128.35±0.5 -19±3 0.2775±0.03 99.1±0.08 
F6 156.4±2.04 -18.5±1.98 0.4505±0.04 98.66±1.2 
F7 141.65±0.7 -18.6±3.2 0.298±0.07 97.7±1.5 
F8 171.5±0.8 -15.9±2.3 0.4365±0.05 99.12±0.55 
F9 294.55±0.3 -15.4±3.4 0.7695±0.01 99.109±0.32 
F10 762.05±1 -16.55±1.7 1±0.05 98.35±1.4 
F11 287.85±2.1 -21.1±2.4 0.4355±0.04 98.7±0.9 
F12 350.55±3 -19.85±3.1 0.3695±0.05 98.86±0.8 
*All values are (mean±SD “standard deviation’’, n= 3). Abbreviations: PS, particle size; ZP, zeta potential; PI, polydispersity index; EE%, entrapment 
efficiency percentage. 
 
Morphology of prepared SLNs by transmission electron 
microscopy (TEM) 
According to statistical analysis, using a design expert (version 11, 
Stat-Ease, Inc) for PS, ZP, PI, and EE %, SLNs (F12, F5) were selected 
for morphological examination. Fig. 2 confirmed the formation of a 
vesicle with a round shape having nano-size particles according to the 
PS measurements. As shown by ZP results, the strong repulsive forces 
between the negatively charged surfaces of prepared SLNs could likely 
explain the non-aggregated nature of the prepared dispersions.
Fig. 2: Transmission electron micrographs of 
Preparation of NAT-SLN loaded gel 
The selected SLNs (F12, F5) were loaded on the ocular 
mucoadhesive gel. Eight gel formulae were succes
using HPMC and Carbapol 940 as viscosity polymers to be evaluated 
to obtain the best form.  
Characterization of the formed NAT-SLN loaded gels
Visual inspection 
All prepared gels were homogenous and white with no pre
Determination of drug content  
The drug content is considered as an indicator
uniformity in any pharmaceutical form. As shown in table 4
results revealed that the drug content of all developed formulation 
was in the accepted range of 90 to 98% as mention
pharmacopeia [34]. All the formulation exhibited fairly uniform drug 
 
Table 4:









*All values are (mean±SD “standard deviation”, n= 3)
 
Fig. 3: In vitro release profile of NAT from SLN loaded gel versus MP
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Determination of mucoadhesive force
Ocular mucoadhesion relies on the interaction of polymer and the 
mucin coat covering the conjunctiva and corneal surface of the eye. 
In this investigation, the mucoadhesive 
which polymers bind to the corneal surface under physiological 
conditions for targeting a drug and
the dosage form [35]. Table 4 
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In vitro NAT release from prepared gels  
The in vitro release of NAT from different gel formulae versus MP is 
illustrated graphically in fig. 3. From the obtained results, it was 
clearly observed that the rate of NAT release from gels sustained up 
to 6 h compering with MP, which indicated that the NAT
gels were capable of controlling the release rate of NAT. There was 
an indirectly proportional relationship between the polymer 
concentrations and the percentage of NAT released from the gel 
form. When semi-solid formulations in a specific type of pol
various concentrations were prepared, the active substance released 
from the formulations decreased as the polymer concentration 
increased. The density of chain structure, which had been observed 
 









*All values are (mean±SD “standard deviation”, n= 3). 
 
In vivo antifungal study 
After 48h from Candida inoculation, the rabbits’
loss of corneal transparency, deep stromal 
stromal edema, and inflammation (fig. 4 a, c). G2 (NAT
‘‘5% Pluronic acid and 1:1 mixed lipid’’ 4HPMC) was recommended 
for further in vivo evaluation. All rabbits in group
for formula MP as rapid release and G2 as sustained
respectively. The right eye of all rabbits received th
responded better and showed improving of the corneal 
transparency, decreasing in size and depth of ulcer
edema (fig. 4 b, d). These results were consistent
the histopathology of specimens taken from the cornea showed in 
 
Fig. 4: a, c) 48h after rabbit’s cornea inoculation
treatment with MP (in usual regimen) showing improvement of 
G2 (every 8h) show
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ymer at 
in gel microstructure, increased at high polymer con
this restricted the active substance moving area resulting in 
decreasing the release of the active substance [37].
In vitro antifungal activity  
Based on NAT-release profile data from the developed gel forms, G1, 
G2, G3, G5, G6, and G7 versus MP were selected for 
study against Candida Albicans. Table 
activity of the different selected forms
Albicans strain. The results showed that G2
Pluronic F127 and 1:1 mixed lipid’’
largest inhibition zone in comparison with the other forms 









Abbreviations: MP, Marketed Product 
 eyes suffered from 
ulcer, surrounding 
-loaded SLN 
s A and B assigned 
-release manner, 
ese forms 
 and stromal 
 with the findings of 
fig. (5 a, b, c). Untreated control 
saline shows severe vascular changes 
large number of fungal spores appear
body’s fig. 5a. Fig. 5b shows a cornea
hydropic changes and leukocyte
compared with the untreated control
specimen of group B shows nearly normal histologic
with no leukocyte infiltration
compared with untreated control
histopathological findings, G2 (NAT
and 1:1 mixed lipid’’ 4% HPMC) provided
fungal keratitis than MP in a controlled release manner
reduce dosing frequency and improve the patient compliance
 with Candida Albicans showing corneal opacity and hypopyon
inflammation and corneal transparency, d,
ing improvement of inflammation and corneal transparency




in vitro antifungal 
5 shows the results of antifungal 
 and MP against Candida 
 containing (NAT-SLN ‘‘5% 
 loaded 4% HPMC gel) had the 
and MP. 
 
corneal specimen that received 
and leukocyte infiltration with 
s as a round faint vesicular 
l specimen of group A with mild 
 infiltration with no fungal spores 
 cornea. In fig. 5c, the corneal 
al structure 
 and absence of the fungal spores 
 cornea. Based on the clinical and 
-loaded SLN ‘‘5% Pluronic F127 
 higher curing effect for 
 up to 8h to 
. 
 
, b) Group, A after 
) Group B after treatment with 
 
Fig. 5a: Corneal stroma showing severe vascular 
leukocyte infiltration with a large number of fungal
the specimen of control untreated cornea
 
Fig. 5b: Corneal stroma showing mild vascular
leukocyte infiltration with no fungal spores
of group A 
 
Fig. 5c: Corneal stroma showing nearly normal his
structure with no leukocyte infiltration and absence
fungal spores from the specimen of group B
 
CONCLUSION 
The ocular bioavailability of NAT was significantly
formulation of NAT-SLN loaded mucoadhesive 
prepared using Pluronic F127 or Tween 80 as a stabilizer and 
Compritol ATO888 and stearic acid as lipids. F12 and F5 showed 
highly stable nanosized, spherical particles with highly 
efficiency. They were chosen as the optimum SLN f
Attia et al. 
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 improved by the 
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entrapment 
orms that 
successfully contributed to mucoadhesive gels using C
or HPMC in different ratios. G2 
lipid SLN’’ 4% HPMC gel) showed the superiority of drug content
mucoadhesive force, and in vitro
gel systems. G2 had the highest 
to other forms that agree with the release study profile.
in vivo and histopathological study
cure percent against fungal keratitis in a controlled release manner 
up to (8 h) comparing with the MP.
considered a good candidate for 
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